News & Trends - Pharmaceuticals
PSA continues to show leadership on ensuring the safe and quality use of medicines
As part of its ongoing commitment to the safe and quality use of medicines, the Pharmaceutical Society of Australia (PSA) recently convened meetings to discuss improvements in the labelling and counselling for antibiotics and opioids by pharmacists.
Attended by medical, government, pharmacy and consumer stakeholders, and chaired by Emeritus Professor Lloyd Sansom AO, the meetings focused on reviewing cautionary advisory labels (CALs) and their associated advice. CALs are a convenient and effective way for pharmacists to reinforce verbal communication with patients about the safe and effective use and storage of medicines.
PSA National President Dr Chris Freeman said the meetings were important in continuing to address the issues of antimicrobial resistance and opioid-related harm.
“Actions three and five of our Pharmacists in 2023 report, look at embedding pharmacists within healthcare teams to improve medicine-related decision making; and advancing pharmacist stewardship of medicine management to improve outcomes at transition of care,” he said.
“Through these measures pharmacists will be empowered to not only play a greater role in addressing antimicrobial resistance and opioid-related harm, but improving the overall safe and quality use of medicines in Australia’s healthcare system.
“This builds on PSA’s position on antibiotics as shown through our Choosing Wisely recommendation 3 – do not dispense a repeat prescription for an antibiotic without first clarifying clinical appropriateness.”
The Australian Pharmaceutical Formulary and Handbook (APF), published by PSA, includes wording for a range of standard CALs and provides guidance on their use for specific medicines. By providing CALs and other written information alongside their professional advice, pharmacists can ensure patients are fully aware of why they are taking a medicine, understand how to take their medicine safely, and have the opportunity to ask questions.
You may also like Keeping premiums low: Towards a sustainable private healthcare system – MTAA welcomes AlphaBeta report
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More